The Annual General Meeting of Arctic Bioscience AS was held Monday 26 May 2025
at 11:00 (CET). All the items on the agenda were addressed and approved.
Attached is the minutes of the Annual General Meeting.
Changes to the Board of Directors:
The General Meeting approved the change in the Board of Directors in accordance
with the board's proposal, thus the Board of Directors will consist of the
following people:
· Harald Nordal (chairperson)
· Jan Endre Vartdal
· Tore A. F. Tønseth
· Marita Holstad
· Olav Sindre Kriken
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.